FDA To Address Companion Dx Development In Separate Guidances
This article was originally published in The Gray Sheet
Executive Summary
FDA hopes to issue draft guidance on companion diagnostics this year, but the document will focus only on the process for adding a diagnostic to an already marketed drug, not simultaneous drug/diagnostic development, according to an agency official.
You may also be interested in...
More Rx, Dx Firms Join Forces On Companion Diagnostics, But Obstacles To European Market Remain
A "highly regionalized payer environment, with variable health technology assessment requirements and an associated reimbursement time lag" is to blame for much of the problem, French industry exec says.
More Rx, Dx Firms Join Forces On Companion Diagnostics, But Obstacles To European Market Remain
While increasing collaborations between drug and diagnostics companies bode well for the future of companion diagnostics, significant reimbursement and regulatory barriers in Europe continue to vex product developers.
More Rx, Dx Firms Join Forces On Companion Diagnostics, But Obstacles To European Market Remain
While increasing collaborations between drug and diagnostics companies bode well for the future of companion diagnostics, significant reimbursement and regulatory barriers in Europe continue to vex product developers.